Learn about Merck’s research into the monoclonal antibody, cetuximab, that induces tumor cell death by blocking the epidermal growth factor receptor (EGFR) and disrupting
EGFR signaling
10 Min
GL-MULO-00228 | December 2025
Welcome to Merck Healthcare!
Help us direct you to the right information by selecting one of the following options: